Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study
Management of chronic myeloid leukaemia (CML) has recently undergone dramatic changes, prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; however, it remains unclear whether real‐world CML management is consistent with these goals. We report results of UK TARGET CML, a retros...
Main Authors: | Milojkovic, D, Cross, NCP, Ali, S, Mead, A, Et al. |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Wiley
2020
|
Similar Items
-
Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK
by: Cross, N, et al.
Published: (2018) -
Simvastatin enhances the efficacy of Bcr-Abl tyrosine kinase inhibitor nilotinib in chronic myeloid leukemia.
by: Koh, Yanqing.
Published: (2011) -
High resolution melt curve analysis as a tool for screening tyrosine kinase domain mutations in patients with chronic myeloid leukemia on tyrosine kinase inhibitors
by: Ang, C.H., et al.
Published: (2010) -
Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial
by: Tan, Bee Kim, et al.
Published: (2020) -
Identifying regulators of chronic myeloid leukaemic (CML) stem cell quiescence and discovering effective novel therapies for CML relapse
by: Xu, Z
Published: (2022)